Managing CML: What HCPs Need to Know
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Managing CML: What HCPs Need to Know
-
Narrated by:
-
Written by:
About this listen
Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Recorded on October 23, 2025
Michael J. Mauro, MD
Director, Chronic Myeloid Leukemia Program
Professor of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!
No reviews yet